Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.
US-based immuno-oncology therapy developer Checkmate Pharmaceuticals has filed to raise up to $75m in an initial public offering on the Nasdaq Global Market that would allow pharmaceutical firm Novo to exit.
Checkmate is working on drugs intended to leverage the body’s immune system to fight solid cancerous tumours. Its lead product candidate, CMP-001, is currently in phase 1b clinical trials.
The IPO proceeds will fund a phase 2 refractory melanoma study as well as development of CMP-001 in naïve front-line…
